The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CGEN Detailed Price Forecast - CNN Money||View CGEN Detailed Summary - Google Finance|
|View CGEN Detailed Summary - Yahoo! Finance||View CGEN Stock Research & Analysis - Zacks.com|
|View CGEN Trends & Analysis - Trade-Ideas||View CGEN Major Holders - Barrons|
|View CGEN Call Transcripts - NASDAQ||View CGEN Breaking News & Analysis - Seeking Alpha|
|View CGEN Annual Report - CompanySpotlight.com||View CGEN OTC Short Report - OTCShortReport.com|
|View CGEN Fundamentals - TradeKing||View CGEN SEC Filings - Bar Chart|
|View Historical Prices for CGEN - The WSJ||View Performance/Total Return for CGEN - Morningstar|
|View the Analyst Estimates for CGEN - MarketWatch||View the Earnings History for CGEN - CNBC|
|View the CGEN Earnings - StockMarketWatch||View CGEN Buy or Sell Recommendations - MacroAxis|
|View the CGEN Bullish Patterns - American Bulls||View CGEN Short Pain Metrics - ShortPainBot.com|
|View CGEN Stock Mentions - StockTwits||View CGEN Stock Mentions - PennyStockTweets|
|View CGEN Stock Mentions - Twitter||View CGEN Investment Forum News - Investor Hub|
|View CGEN Stock Mentions - Yahoo! Message Board||View CGEN Stock Mentions - Seeking Alpha|
|View Insider Transactions for CGEN - SECform4.com||View Insider Transactions for CGEN - Insider Cow|
|View CGEN Major Holdings Summary - CNBC||View Insider Disclosure for CGEN - OTC Markets|
|View Insider Transactions for CGEN - Yahoo! Finance||View Institutional Holdings for CGEN - NASDAQ|
|View CGEN Stock Insight & Charts - FinViz.com||View CGEN Investment Charts - StockCharts.com|
|View CGEN Stock Overview & Charts - BarChart||View CGEN User Generated Charts - Trading View|
Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy
Posted on Thursday April 19, 2018
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.
HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen.
Benzinga Pro's 5 Stocks To Watch Today
Posted on Monday April 02, 2018
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program.